JP2998102B2 - Anti-dementia agent containing yeast extract - Google Patents
Anti-dementia agent containing yeast extractInfo
- Publication number
- JP2998102B2 JP2998102B2 JP2189409A JP18940990A JP2998102B2 JP 2998102 B2 JP2998102 B2 JP 2998102B2 JP 2189409 A JP2189409 A JP 2189409A JP 18940990 A JP18940990 A JP 18940990A JP 2998102 B2 JP2998102 B2 JP 2998102B2
- Authority
- JP
- Japan
- Prior art keywords
- yeast extract
- reishi
- dementia agent
- extract
- agent containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【発明の詳細な説明】 （産業上の利用分野） 本発明は、酵母エキスを含有する抗痴呆剤に関する。Description: TECHNICAL FIELD The present invention relates to an anti-dementia agent containing a yeast extract.
（従来の技術） 漢方薬である霊芝（学名：マンネンタケ:Ganoderma L
ucidum Curter Fr.KARST）は、中国において古来より不
老長寿の霊験あらたかな“神薬”として用いられてき
た。近年では、霊芝に抗老化作用が存在することを証明
するため、その科学的解明が盛んに行われている。その
結果、老化に関する研究の一側面である免疫学的研究に
よって、霊芝はインターロイキン−２（Interleukin−
２）産生能上昇作用、ナチュラルキラー細胞（Natural
killer cell）の活性化作用（坪倉道明ら：和漢薬学会
誌、５,522−523,1988）、さらに、顕著な抗腫瘍活性化
作用（荻田善一ら:Therapeutic Research,８,845−852,
1988）を有することが判明した。すなわち、霊芝は抗老
化作用の一つとして免疫賦活作用を有することが明らか
になったのである。また、老化のもう一つの側面である
痴呆の研究により、霊芝には、加齢による学習・記憶機
能の低下を遅延させる作用のあることが判明している
（荻田善一ら：老化促進モデルマウス（SAM）研究協議
会抄録集、５,27−28,1988）。これらのことから霊芝の
抗老化作用が科学的に立証されている。(Conventional technology) Reishi (scientific name: Mannentake: Ganoderma L)
ucidum Curter Fr.KARST) has been used in China since ancient times as a new “god medicine” for aging longevity. In recent years, scientific elucidation has been actively carried out to prove the existence of an anti-aging effect in Reishi. As a result, the immunological study, one aspect of aging research, revealed that Reishi was able to interleukin-2 (Interleukin-
2) Increased production ability, natural killer cells (Natural
killer cell) (Michiaki Tsubokura et al .: Wako Pharmaceutical Association, 5 , 522-523, 1988), and a remarkable antitumor activating effect (Zenichi Ogita et al .: Therapeutic Research, 8 , 845-852,
1988). That is, it has been revealed that Reishi has an immunostimulating effect as one of the anti-aging effects. In addition, research on dementia, another aspect of aging, has revealed that Reishi has an effect of delaying the decline of learning and memory functions due to aging (Ogita et al .: Aging promotion model) Mouse (SAM) Research Council Abstracts, 5 , 27-28, 1988). From these facts, the anti-aging effect of Reishi is scientifically proven.
自然界において霊芝は、古木十万本に２〜３本しか採
取できないという貴重品でめったに人目に触れるもので
はなかったが、約20年前より栽培法が確立され、良質の
霊芝が利用できるようになり、医薬組成物としての有用
性が近年高まってきた。In the natural world, ganoderma is a rare item that is rarely noticeable because it can collect only a few hundred trees per 100,000 old trees, but cultivation methods have been established about 20 years ago, and good quality ganoderma can be used As a result, its usefulness as a pharmaceutical composition has been increasing in recent years.
一方、酵母エキスは蛋白質、脂質、有機酸、アミノ
酸、ビタミン、ミネラル、糖質、核酸関連物質などの有
用な成分を含んでおり、微生物培養の培地や動物の飼料
の素材などとして用いられている。また、熱、水分、他
の添加物などから大きな影響を受けないことから、加工
に適し、さらに抗酸化作用も有している。On the other hand, yeast extract contains useful components such as proteins, lipids, organic acids, amino acids, vitamins, minerals, carbohydrates, and nucleic acid-related substances, and is used as a medium for microbial culture and as a raw material for animal feed. . In addition, since it is not largely affected by heat, moisture, other additives, etc., it is suitable for processing and has an antioxidant effect.
（発明が解決しようとする課題） このような酵母エキスの利点を生かし、漢方薬と組み
合わせた医薬組成物は今までなかった。そこで、本発明
は、酵母エキスに漢方薬、特に霊芝を含有させることに
より、栄養価に富む酵母エキスの有用成分が霊芝等の漢
方薬の薬効を増強させ、しかも、組成物の物理化学的な
安全性を高めるように、酵母エキスを含有した医薬組成
物を得ることを目的とした。(Problems to be Solved by the Invention) There has been no pharmaceutical composition that combines the advantages of such a yeast extract with a Chinese medicine. Thus, the present invention provides a yeast extract containing a Chinese medicine, particularly a reishi, thereby increasing the usefulness of a nutrient-rich yeast extract to enhance the medicinal properties of a Chinese medicine such as Reishi, and furthermore, the physicochemical properties of the composition. An object was to obtain a pharmaceutical composition containing a yeast extract so as to enhance safety.
（課題を解決するための手段） 本発明は、漢方薬、好ましくは霊芝と酵母エキスを含
有することを特徴とする酵母エキス含有抗痴呆剤であ
る。(Means for Solving the Problems) The present invention is a yeast extract-containing anti-dementia agent comprising a Chinese medicine, preferably a reishi and a yeast extract.
本発明でいう霊芝はそのまま粉末状にしたもの、熱水
抽出したもの、エーテル抽出したもの等が用いられる
が、特に霊芝を熱水抽出し熱時ろ過処理したものを用い
ると良い。The ganoderma in the present invention may be powdered as it is, extracted with hot water, extracted with ether, and the like. In particular, it is preferable to use a reishi that has been subjected to hot water extraction and hot filtration.
酵母エキスは酵母サッカロミセス・セレビシエ（Sacc
haromyces cerevisiae）から抽出したものであればどの
ようなものでも利用できる。その中でも、乾燥酵母1g中
に蛋白質400mg以上およびチアミン（塩酸チアミンとし
て）100μｇ以上を含んでいることから、ビール酵母か
ら抽出したエキスが特に好ましい。Yeast extract is yeast Saccharomyces cerevisiae (Sacc
haromyces cerevisiae) can be used. Among them, an extract extracted from brewer's yeast is particularly preferable because 1 g of dry yeast contains 400 mg or more of protein and 100 µg or more of thiamine (as thiamine hydrochloride).
酵母エキスは粉末状、ペースト状または液体状のもの
が利用できるが、医薬組成物の製造の観点から粉末状の
酵母エキスを利用するのが好ましい。The yeast extract can be used in the form of powder, paste or liquid, but it is preferable to use powdered yeast extract from the viewpoint of production of a pharmaceutical composition.
本発明の抗痴呆剤の製造法は以下のとおりである。す
なわち、霊芝を霊芝の約20倍量（重量比）の水で熱水抽
出を行い、水量が半分になるまで煮沸する。それを凍結
乾燥した物を霊芝エキスとして用いる。また、酵母エキ
スは、ビール醗酵工程から副生した生酵母を水酸化ナト
リウムや水で脱苦味洗浄し、その精製生酵母を自己消化
させ、その自己消化液を菌体分離ろ過、濃縮、ろ過、乾
燥したものを用いる。そして、霊芝エキスおよび酵母エ
キス、さらに所望により乳糖、でんぷんなどの賦形剤な
どを混合する。The method for producing the anti-dementia agent of the present invention is as follows. In other words, hot water extraction is carried out on the reishi with about 20 times the weight (weight ratio) of the reishi, and the water is boiled until the amount of water is reduced to half. The freeze-dried product is used as Reishi extract. In addition, the yeast extract is debitterly washed with sodium hydroxide or water to remove the live yeast produced as a by-product from the beer fermentation process, autolyzes the purified live yeast, and separates, filters, concentrates, and filters the autolysate from the autolysate. Use the dried one. Then, a reishi extract and a yeast extract, and if necessary, excipients such as lactose and starch are mixed.
酵母エキスと霊芝の割合は、霊芝１重量部に対し酵母
エキスを0.1〜10重量部使用することが好ましい。0.1重
量部より小さい場合は、酵母エキスによる薬効増強作用
が認められず、また、10重量部を超えると、酵母エキス
によるさらなる増強作用が認められないので好ましくな
い。The ratio of yeast extract to reishi is preferably 0.1 to 10 parts by weight of yeast extract per 1 part by weight of reishi. If the amount is less than 0.1 part by weight, the effect of enhancing the efficacy of the yeast extract is not recognized.
本発明の抗痴呆剤は経口剤として錠剤、カプセル剤、
顆粒、細粒、シロップ剤等、注射剤としては無菌溶液剤
または懸濁液剤で処方される。用量は、霊芝原生薬換算
量1g〜5gを全日量とし、１日数回にわけて用いるのが好
ましい。The anti-dementia agent of the present invention is a tablet, capsule,
Injectables such as granules, fine granules and syrups are formulated as sterile solutions or suspensions. The dose is preferably 1 g to 5 g in terms of the total amount of the reishi grass crude drug, and is preferably used several times a day.
（実施例） 本発明の抗痴呆剤の処方の一例を次に示す。(Example) An example of the formulation of the anti-dementia agent of the present invention is shown below.
（１） 霊芝熱水抽出エキス 45g （原生薬換算 霊芝 500g） （２） 酵母エキス 90g （３） 乳糖 115g 全量 250g 成分（１）、（２）および（３）を混和し、混合物を
圧縮錠剤機で圧縮して錠剤１錠あたり成分（１）を45mg
含有する錠剤を1000個製造した。得られた錠剤は、２錠
×３回／日で経口使用する。(1) Reishi hot water extract 45g (proteus equivalent reishi 500g) (2) Yeast extract 90g (3) Lactose 115g total amount 250g Combine ingredients (1), (2) and (3) and compress the mixture Compress with a tablet machine, 45mg of component (1) per tablet
1000 tablets were produced. The obtained tablets are used orally at 2 tablets × 3 times / day.
（試験例） 老化促進モデルマウス（Senescence Accelerated Mou
se:SAM）であるSAM−P/8系マウスをA,B,C（各７匹）,D
（６匹）の４群に分け、表１の混合飼料を一定期間自由
摂取させた後、学習・記憶試験を行った。(Test Example) Senescence Accelerated Mou
se: SAM), A, B, C (7 each), D
(6 animals) were divided into four groups, and the mixed feed of Table 1 was freely taken for a certain period of time, and then a learning / memory test was performed.
ここで、市販の粉末飼料CE−２の組成は、水分8.7
％、粗蛋白質24.8％、粗脂肪4.4％、粗繊維3.5％、粗灰
分7.0％、可溶性窒素物51.6％で、カロリーは100g当り3
45.2Calである。 Here, the composition of commercially available powdered feed CE-2 has a water content of 8.7.
%, Crude protein 24.8%, crude fat 4.4%, crude fiber 3.5%, crude ash 7.0%, soluble nitrogen 51.6%, calories 3 per 100g
45.2 Cal.
また、ここで、霊芝熱水抽出エキスは、霊芝粉末100
重量部を熱水抽出後凍結乾燥して、８重量部の霊芝熱水
抽出エキスとしたものである。Also, here, Lingzhi hot water extraction extract is Lingzhi powder 100
A part by weight was extracted with hot water and then freeze-dried to obtain an extract of 8 parts by weight of Reishi hot water extract.
投与条件は、４ヶ月齢のマウスに１ヶ月間の短期投与
とした。The administration conditions were short-term administration for one month to 4-month-old mice.
学習・記憶試験は受動的回避反応実験により行った。
すなわち、第１日目、マウスをシャトルケージの明室に
入れ、３分間放置してケージに馴らした。第２日目、マ
ウスをシャトルケージの明室に置き、暗室内に完全に入
るまでの時間（反応潜時）を測定し、獲得試行の結果を
得た。マウスが暗室に入ると同時に戸を閉め、３秒間1.
0mAの電撃ショックを与えた。第３日目、マウスをシャ
トルケージの明室に置き、暗室内に完全に入るまでの反
応潜時を測定し、再生試行の結果を得た。受動的回避実
験前に予め自発的運動量を測定した。Learning and memory tests were performed by passive avoidance response experiments.
That is, on the first day, the mice were placed in the light room of the shuttle cage and left for 3 minutes to adjust to the cage. On the second day, the mice were placed in the bright room of the shuttle cage, and the time required to completely enter the dark room (reaction latency) was measured to obtain the results of the acquisition trial. Close the door as soon as the mouse enters the darkroom and 1.
A shock shock of 0 mA was given. On the third day, the mice were placed in the light room of the shuttle cage, the reaction latency until the mice completely entered the dark room was measured, and the results of the reproduction trial were obtained. Spontaneous locomotor activity was measured before the passive avoidance experiment.
結果を表２に示す。 Table 2 shows the results.
表２から明らかなように、CE−２投与群（Ａ群）と比
較して、霊芝熱水抽出エキス含有CE−２投与群（Ｂ群）
では、再生試行の反応潜時の有意な延長はみられなかっ
た。また乾燥ビール酵母エキス10％含有CE−２投与群
（Ｃ群）においても再生試行の反応潜時の有意な延長は
みられなかったのに対し、霊芝熱水抽出エキス＋乾燥ビ
ール酵母エキス10％含有CE−２投与群（Ｄ群）は再生試
行の反応潜時の有意な延長を示した。すなわち、酵母エ
キスによる霊芝の学習・記憶低下遅延作用の増強がみら
れた。 As is clear from Table 2, the CE-2 administration group containing the Ganoderma lucidum hot water extract (Group B) was compared with the CE-2 administration group (Group A).
Did not significantly increase the response latency of the regeneration trial. In the CE-2 administration group containing 10% of dry beer yeast extract (Group C), the reaction latency of the regeneration trial was not significantly prolonged. The% -containing CE-2 administration group (Group D) showed a significant increase in the response latency of the regeneration trial. That is, the effect of the yeast extract on delaying the learning and memory decline of Reishi was observed.
（発明の効果） 本発明の抗痴呆剤は、従来の霊芝に酵母エキスを添加
することによって霊芝単独で使用した時よりもさらに優
れた学習・記憶機能への効果をもつものであって、抗痴
呆剤として有効である。(Effect of the Invention) The anti-dementia agent of the present invention has a more excellent effect on learning and memory functions by adding a yeast extract to a conventional reishi, than when used alone. It is effective as an anti-dementia agent.
Claims (3)
する抗痴呆剤。[1] An anti-dementia agent comprising reishi and yeast extract.
項１記載の抗痴呆剤。2. The anti-dementia agent according to claim 1, wherein the yeast extract is a brewer's yeast extract.
0重量部含有することを特徴とする請求項１記載の抗痴
呆剤。3. A yeast extract is added in an amount of 0.1 to 1 with respect to 1 part by weight of Reishi.
2. The anti-dementia agent according to claim 1, which contains 0 parts by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2189409A JP2998102B2 (en) | 1990-07-19 | 1990-07-19 | Anti-dementia agent containing yeast extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2189409A JP2998102B2 (en) | 1990-07-19 | 1990-07-19 | Anti-dementia agent containing yeast extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0477430A JPH0477430A (en) | 1992-03-11 |
| JP2998102B2 true JP2998102B2 (en) | 2000-01-11 |
Family
ID=16240791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2189409A Expired - Fee Related JP2998102B2 (en) | 1990-07-19 | 1990-07-19 | Anti-dementia agent containing yeast extract |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2998102B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102240365A (en) * | 2010-05-14 | 2011-11-16 | 湖南瑞丹科技有限公司 | Pharmaceutical composition for enhancing organism immunity and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4867043B2 (en) * | 2004-01-30 | 2012-02-01 | 沖縄県 | Brain function improving agent and food using yeast extract fraction |
-
1990
- 1990-07-19 JP JP2189409A patent/JP2998102B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102240365A (en) * | 2010-05-14 | 2011-11-16 | 湖南瑞丹科技有限公司 | Pharmaceutical composition for enhancing organism immunity and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0477430A (en) | 1992-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6316002B1 (en) | Germination activated red Ganoderma lucidum spores and method for producing the same | |
| KR101908381B1 (en) | Traditional chinese medicine combination for regulation immune function and preparation method therefor | |
| TWI527586B (en) | Use of an antrodia cinnamomea (antrodia camphorata or taiwanofungus camphoratus) extract for preparing a drug for modulating th17 cells | |
| KR100908738B1 (en) | A method for extracting β-glucan of Astragalus and feed composition comprising the β-glucan | |
| WO2020177389A1 (en) | Ergothioneine-containing hericium erinaceus health product formulation and preparation method therefor | |
| CN111657501A (en) | Oyster peptide cordyceps sinensis mycelium composition with function of enhancing immunity and application thereof | |
| KR101729003B1 (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
| JP2998102B2 (en) | Anti-dementia agent containing yeast extract | |
| US5603937A (en) | Immune-enhancing food comprising isaria type insect raised fungus (cordyceps japonensis) as a main ingredient | |
| CN109232758B (en) | Pleurotus citrinopileatus mushroom bran polysaccharide and extraction process and application thereof | |
| WO1998056755A1 (en) | Physiologically active substances tkr2449, process for producing the same, and microorganism | |
| KR100814351B1 (en) | Physiologically active compositions of Basidiomycotina and Araliaceae extracts | |
| CN116515005A (en) | Morchella polysaccharide, its preparation method and application in preparing medicament for preventing and/or improving antidepressant | |
| JP2002114701A (en) | Composition for improving lipid metabolism | |
| CN111494255B (en) | Composition containing ginseng cordyceps sinensis fermentation extract and application of composition in cosmetics | |
| CN113521262A (en) | Lysozyme preparation with anti-inflammatory effect | |
| TW202315643A (en) | Use of extract of fruit body ofcordyceps militarisfor manufacturing medication for improving anti-blue light damage effect | |
| CN112293740A (en) | Composition for enhancing immunity and preparation method and application thereof | |
| US6893641B2 (en) | Ganoderma lucidum spores for treatment of autoimmune diseases | |
| JP4323128B2 (en) | Bioactive composition | |
| CN109674942A (en) | A kind of Antilipidemic pharmaceutical compositions, preparation method and applications | |
| TWI618540B (en) | Composition for preventing renal toxicity caused by drug toxicity, preparation method thereof and Its use | |
| CN102860497A (en) | Functional Pleurotus eryngii food and preparation method thereof | |
| JPS62209023A (en) | Antiallergic agent | |
| JP2002249437A (en) | Health builder and composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |